athx20231010

0001437749-23-028018.txt : 20231011 0001437749-23-028018.hdr.sgml : 20231011 20231011092744 ACCESSION NUMBER: 0001437749-23-028018 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231010 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231011 DATE AS OF CHANGE: 20231011 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ATHERSYS, INC / NEW CENTRAL INDEX KEY: 0001368148 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 204864095 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33876 FILM NUMBER: 231319567 BUSINESS ADDRESS: STREET 1: 3201 CARNEGIE AVENUE CITY: CLEVELAND STATE: OH ZIP: 44115-2634 BUSINESS PHONE: 216-431-9900 MAIL ADDRESS: STREET 1: 3201 CARNEGIE AVENUE CITY: CLEVELAND STATE: OH ZIP: 44115-2634 FORMER COMPANY: FORMER CONFORMED NAME: BTHC VI Inc DATE OF NAME CHANGE: 20060629 8-K 1 athx20231010_8k.htm FORM 8-K athx20231010_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 10, 2023

Athersys, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-33876	20-4864095
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

3201 Carnegie Avenue, Cleveland, Ohio				44115-2634
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (216) 431-9900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.001 per share	ATHX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement

On October 10, 2023, ABT Holding Company, a wholly-owned subsidiary (“ABT Holding”) of Athersys, Inc. (the “Company”), and HEALIOS K.K. (“Healios”) entered into a binding memorandum of understanding (the “MOU”), pursuant to which, among other things, ABT Holding has entered into (i) an amendment (the “Fifth Amendment to License Agreement”) to that certain license agreement, dated as of January 8, 2016, as amended (the “Existing License Agreement”), and (ii) an assignment agreement for ARDS (as defined below) clinical doses (the “Assignment Agreement”), each with Healios and dated of even date with the MOU.

Under the Fifth Amendment to License Agreement, the Company agreed to grant Healios a non-exclusive worldwide license to develop and commercialize MultiStem with respect to treating acute respiratory distress syndrome (“ARDS”) in exchange for potential development and sales milestone payments and additional royalties totaling up to $150 million in the aggregate. The Assignment Agreement provides for ABT Holding’s assignment of certain MultiStem doses manufactured by using a 3D bioreactor process to Healios. ABT Holding expects to receive between $1.5 million and $4.5 million in near term payments.

Copies of the MOU, the Fifth Amendment to License Agreement and the Assignment Agreement will be filed as exhibits to the Company’s next periodic report, and the description of such documents is qualified in its entirety by reference to such exhibits.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains statements that are, or may be deemed, “forward-looking statements.” Forward-looking statements generally use forward-looking words, such as “may,” “will,” “could,” “should,” “would,” “project,” “believe,” “anticipate,” “expect,” “estimate,” “continue,” “potential,” “plan,” “forecast” and other words that convey the uncertainty of future events or outcomes. These forward-looking statements are not guarantees of the Company’s future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict and may be outside of the Company’s control. Therefore, the actual outcomes and results may differ materially from those expressed in or contemplated by the forward-looking statements. Any forward-looking statement speaks only as of the date of this Current Report on Form 8-K. Except as may be required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and investors are cautioned not to rely upon them unduly.

Item 8.01 Other Events

On October 10, 2023, the Company issued a press release regarding interim analysis results of the MASTERS-2 clinical study and the signing of the MOU. A copy of the press release is filed as Exhibit 99.1 hereto and is hereby incorporated herein by reference, other than the quotations by Dan Camardo.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated October 10, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 11, 2023

	ATHERSYS, INC.

	By:	/s/ Daniel Camardo
		Daniel Camardo Chief Executive Officer and Duly Authorized Officer

EX-99.1 2 ex_578513.htm EXHIBIT 99.1 ex_578513.htm

Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestones

CLEVELAND (October 10, 2023) – Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company’s ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365. There were no safety issues identified. Because the sample size required to achieve statistical significance is considerably larger, Athersys intends to conduct additional data analysis with independent statisticians. The Company plans to pause enrollment of new patients while this analysis is being conducted.

Separately, Athersys announces that it has entered into a Memorandum of Understanding (MOU) granting HEALIOS K.K. (Healios) global rights to develop and commercialize MultiStem for the treatment of acute respiratory distress syndrome (ARDS). Under the terms of the MOU, Athersys will receive between $1.5M and $4.5M in near term payments with up to $150 million in potential development and sales milestones and additional royalties. Athersys also expects to receive revenue from the sale of existing clinical doses of MultiStem-- which were manufactured in accordance with its 3D bioreactor process that earlier this year received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)--for Healios to use in its Phase 3 clinical trial in ARDS.

Athersys intends to continue exploring available strategic options. However, in the event Athersys is unable in the near-term to enter into a strategic transaction or obtain adequate financing, it expects to have to file for protection under the bankruptcy laws to allow the Company to conduct an orderly wind down of operations. In the interim, the Company is streamlining its operations to preserve its capital and cash resources.

“I’d like to thank the many patients, clinicians and vendors that have supported this pivotal phase 3 trial since its start in 2018. We’re disappointed with the results of the unblinded interim analysis indicating a large sample size adjustment would be required to achieve our primary endpoint. We intend to conduct further analysis to better understand these results. The new MOU we’ve signed with Healios for ARDS provides the company near-term capital and the potential for meaningful milestone payments as we continue to pursue various strategic solutions” said Dan Camardo, Chief Executive Officer of Athersys.

About MultiStem®

MultiStem® (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy’s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Athersys is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about Athersys on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in Athersys to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about Athersys on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the anticipated use of grant funding, the anticipated completion of any study or studies funded using grant funding, the anticipated outcome of any study or studies funded using grant funding, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “suggest,” “will,” or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. In addition, a number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face are the risk that we will be unable to raise capital to fund our operations in the near term and long term, including our ability to obtain funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, on terms acceptable to us or at all, and to continue as a going concern. The following risks and uncertainties may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements: our ability to raise capital to fund our operations in the near term and long term, including our ability to obtain funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, on terms acceptable to us or at all, and to continue as a going concern; whether we receive a grant from BARDA; our collaborators’ ability and willingness to continue to fulfill their obligations under the terms of our collaboration agreements and generate sales related to our technologies; the possibility of unfavorable results from ongoing and additional clinical trials involving MultiStem; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in an early stage clinical trial may not be predictive of results in later stage or large scale clinical trials; our ability to successfully license our SIFU technology; our ability to regain and maintain compliance with the Nasdaq continued listing requirements; the timing and nature of results from MultiStem clinical trials, including the MASTERS-2 Phase 3 clinical trial evaluating the administration of MultiStem for the treatment of ischemic stroke; our ability to meet milestones and earn royalties under our collaboration agreements, including the success of our collaboration with Healios; the MATRICS-1 clinical trial being conducted with The University of Texas Health Science Center at Houston evaluating the treatment of patients with serious traumatic injuries; the availability of product sufficient to meet our clinical needs and potential commercial demand following any approval; the possibility of delays in, adverse results of, and excessive costs of the development process; our ability to successfully initiate and complete clinical trials of our product candidates; the possibility of delays, work stoppages or interruptions in manufacturing by third parties or us, such as due to material supply constraints, contamination, operational restrictions due to COVID-19 or other public health emergencies, labor constraints, regulatory issues or other factors that could negatively impact our trials and the trials of our collaborators; uncertainty regarding market acceptance of our product candidates and our ability to generate revenues, including MultiStem cell therapy for neurological, inflammatory and immune, cardiovascular and other critical care indications; changes in external market factors; changes in our industry’s overall performance; changes in our business strategy; our ability to protect and defend our intellectual property and related business operations, including the successful prosecution of our patent applications and enforcement of our patent rights, and operate our business in an environment of rapid technology and intellectual property development; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; the success of our efforts to enter into new strategic partnerships and advance our programs; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; the ability to execute our strategic review process; the success of our competitors and the emergence of new competitors; and the risks mentioned elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2022 under Item 1A, “Risk Factors” and our other filings with the U.S. Securities and Exchange Commission. You should not place undue reliance on forward-looking statements, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Athersys

Ellen Gurley

Manager of Corporate Communications and Investor Relations

ir@athersys.com

LHA Investor Relations

Tirth T. Patel

212-201-6614

EX-101.SCH 3 athx-20231010.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 athx-20231010_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 athx-20231010_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 athx-20231010_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	Oct. 10, 2023
Document Information [Line Items]
Entity, Registrant Name	ATHERSYS, INC / NEW
Document, Type	8-K
Document, Period End Date	Oct. 10, 2023
Entity, Incorporation, State or Country Code	DE
Entity, File Number	001-33876
Entity, Tax Identification Number	20-4864095
Entity, Address, Address Line One	3201 Carnegie Avenue
Entity, Address, City or Town	Cleveland
Entity, Address, State or Province	OH
Entity, Address, Postal Zip Code	44115-2634
City Area Code	216
Local Phone Number	431-9900
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	ATHX
Security Exchange Name	NASDAQ
Entity, Emerging Growth Company	false
Amendment Flag	false
Entity, Central Index Key	0001368148

XML 8 athx20231010_8k_htm.xml IDEA: XBRL DOCUMENT 0001368148 2023-10-10 2023-10-10 false 0001368148 ATHERSYS, INC / NEW 8-K 2023-10-10 DE 001-33876 20-4864095 3201 Carnegie Avenue Cleveland OH 44115-2634 216 431-9900 false false false false Common Stock ATHX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.athx.com/20231010/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports athx-20231010.xsd athx-20231010_def.xml athx-20231010_lab.xml athx-20231010_pre.xml athx20231010_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "athx20231010_8k.htm": { "nsprefix": "athx", "nsuri": "http://www.athx.com/20231010", "dts": { "schema": { "local": [ "athx-20231010.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "athx-20231010_def.xml" ] }, "labelLink": { "local": [ "athx-20231010_lab.xml" ] }, "presentationLink": { "local": [ "athx-20231010_pre.xml" ] }, "inline": { "local": [ "athx20231010_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.athx.com/20231010/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20238K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "div", "body", "html" ], "reportCount": 1, "baseRef": "athx20231010_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20238K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "div", "body", "html" ], "reportCount": 1, "baseRef": "athx20231010_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.athx.com/20231010/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001437749-23-028018-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-028018-xbrl.zip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